![]() |
市場調查報告書
商品編碼
1633542
禽流感疫苗市場規模佔有率、按疫苗類型、應用、菌株、給藥途徑、目標類型、配銷通路和地區分類的成長分析 - 行業預測,2025 年至 2032 年Avian Influenza Vaccine Market Size, Share, Growth Analysis, By Vaccine Type, By Application, By Strain, By Administration Route, By Target Species, By Distribution Channel, By Region - Industry Forecast 2025-2032 |
2023 年全球禽流感疫苗市場規模價值為 1,458.8 億美元,預計將從 2024 年的 1,520.1 億美元成長到 2032 年的 2,112.5 億美元,預測期內(2025-2032 年)的複合年成長率為 4.2%。
禽流感主要由 H5N1 病毒株引起,其起源可追溯到水禽,並首次在中國發現,對中國家禽乃至人類健康構成重大風險。這種疾病有可能在全球蔓延,影響歐洲、亞洲和美洲的市場。禽流感疫苗包括H5、H7和H9疫苗,是控制疾病所必需的,中國是最大的生產國。同時,在美國,肝硬化影響了0.27%的成年人口,其中69%的人沒有症狀。主要風險因素包括糖尿病、酗酒和病毒性肝炎,與對照組相比,疾病的死亡率明顯較高,凸顯了緊迫的公共衛生需求。
Global Avian Influenza Vaccine Market size was valued at USD 145.88 billion in 2023 and is poised to grow from USD 152.01 billion in 2024 to USD 211.25 billion by 2032, growing at a CAGR of 4.2% during the forecast period (2025-2032).
Avian influenza, primarily driven by the H5N1 strain, poses significant risks to both domestic poultry and potential human health, with its origins traced back to waterfowl and an initial detection in China. The disease has the potential to spread globally, impacting markets across Europe, Asia, and the Americas. Vaccination strategies are crucial; the H5, H7, and H9 avian influenza vaccines are vital in disease control, with China emerging as the largest producer. Concurrently, in the U.S., cirrhosis affects 0.27% of the adult population, with a striking 69% unaware of their condition. Key risk factors include diabetes, alcohol abuse, and viral hepatitis, highlighting urgent public health needs as this condition carries a significantly higher mortality rate compared to matched control groups.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Avian Influenza Vaccine market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Avian Influenza Vaccine Market Segmental Analysis
Global Avian Influenza Vaccine Market is segmented by Vaccine Type, Application, Strain, Administration Route, Target Species, Distribution Channel and region. Based on Vaccine Type, the market is segmented into Inactivated Vaccines, Live Recombinant Vaccines, Combination Vaccines, Recombinant Vaccines and Subunit Vaccines. Based on Application, the market is segmented into Chicken, Duck and Goose, Turkey and Others. Based on Strain, the market is segmented into H5 Strain, H7 Strain and H9 Strain. Based on Administration Route, the market is segmented into Intramuscular, Subcutaneous and Waterborne. Based on Target Species, the market is segmented into Broilers, Layers, Breeders and Backyard Poultry. Based on Distribution Channel, the market is segmented into Veterinary Clinics, Online Pharmacies and Retail Stores. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Avian Influenza Vaccine Market
The global avian influenza vaccine market is primarily driven by the escalating incidence of avian influenza, a disease caused by the avian influenza virus type A, predominantly found in waterfowl and transmissible to domestic chickens and various bird species. This virus can be categorized based on its surface proteins into subtypes of neuraminidase (NA) and hemagglutinin (HA), leading to classifications of highly pathogenic and low pathogenicity viruses. Despite nonpathogenic strains typically causing no visible symptoms, highly pathogenic variants pose a significant threat, resulting in severe disease outbreaks and high mortality rates in poultry, thereby underscoring the urgent need for effective vaccination.
Restraints in the Global Avian Influenza Vaccine Market
The Global Avian Influenza Vaccine market faces significant restraints due to the challenges posed by the rapid mutation of the avian influenza virus. This high mutation rate complicates efforts to ensure effective vaccine coverage, as the vaccines may become less effective against emerging strains. Consequently, ongoing research is crucial to comprehend the virus's dynamics and to enhance vaccine formulation and efficacy. As researchers strive to adapt to these viral changes, the demand for innovative solutions in vaccine development becomes increasingly essential, highlighting the need for continuous investment in avian influenza research to bolster public health responses to this ongoing threat.
Market Trends of the Global Avian Influenza Vaccine Market
The Global Avian Influenza Vaccine market is witnessing significant growth, particularly in the Asia-Pacific region, driven by countries like Israel, China, India, and South Korea, which report high incidences of bird flu viruses. The region's increasing focus on enhancing supply chain efficiencies and bolstering research and development through favorable government policies is expected to accelerate vaccine production and distribution. Furthermore, rising awareness around biosecurity measures in poultry farming and the necessity for preventive health strategies further stimulate market demand. This combination of factors is poised to shape a robust market trend, promoting innovation in avian influenza vaccines on a global scale.